Cancer immunotherapy–related adverse events: Causes and challenges Review


Authors: Blidner, A. G.; Choi, J.; Cooksley, T.; Dougan, M.; Glezerman, I.; Ginex, P.; Girotra, M.; Gupta, D.; Johnson, D.; Shannon, V. R.; Suarez-Almazor, M.; Rapoport, B. L.; Anderson, R.
Review Title: Cancer immunotherapy–related adverse events: Causes and challenges
Abstract: Despite the success and ongoing promise of monoclonal antibody–targeted immune checkpoint inhibitor immunotherapy of advanced malignancies, in particular, antibodies directed against CTLA-4 and PD-1/PD-L1, the development of immune-related adverse events (irAEs) remains a constraint of this type of therapy. Although rarely fatal, the occurrence of irAEs may necessitate discontinuation of immunotherapy, as well as administration of corticosteroids or other immunosuppressive therapies that may not only compromise efficacy but also predispose for development of opportunistic infection. Clearly, retention of efficacy of immune checkpoint–targeted therapies with concurrent attenuation of immune-mediated toxicity represents a formidable challenge. In this context, the current brief review examines mechanistic relationships between these events, as well as recent insights into immunopathogenesis, and strategies which may contribute to resolving this issue. These sections are preceded by brief overviews of the discovery and functions of CTLA-4 and PD-1, as well as the chronology of the development of immunotherapeutic monoclonal antibodies which target these immune checkpoint inhibitors. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
Keywords: ipilimumab; microbiome; nivolumab; cytotoxic t-lymphocyte-associated protein 4 (ctla-4); programmed cell death protein 1 (pd-1); regulatory t lymphocytes (tregs)
Journal Title: Supportive Care in Cancer
Volume: 28
Issue: 12
ISSN: 0941-4355
Publisher: Springer Verlag  
Date Published: 2020-12-01
Start Page: 6111
End Page: 6117
Language: English
DOI: 10.1007/s00520-020-05705-5
PUBMED: 32857220
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 December 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Monica Girotra
    22 Girotra
  2. Dipti Gupta
    55 Gupta